DK166541B1 - Fremgangsmaade til isolering af isosilybinfrit silibinin - Google Patents
Fremgangsmaade til isolering af isosilybinfrit silibinin Download PDFInfo
- Publication number
- DK166541B1 DK166541B1 DK537685A DK537685A DK166541B1 DK 166541 B1 DK166541 B1 DK 166541B1 DK 537685 A DK537685 A DK 537685A DK 537685 A DK537685 A DK 537685A DK 166541 B1 DK166541 B1 DK 166541B1
- Authority
- DK
- Denmark
- Prior art keywords
- anhydrous
- ceph
- aminothiazol
- acetamido
- carboxyprop
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 claims description 10
- -1 2-aminothiazol-4-yl Chemical group 0.000 claims description 7
- 150000004686 pentahydrates Chemical class 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000005169 Debye-Scherrer Methods 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- 238000010586 diagram Methods 0.000 claims description 3
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 2
- 238000005452 bending Methods 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 description 10
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960003547 ceftazidime pentahydrate Drugs 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YUPQOCKHBKYZMN-UHFFFAOYSA-N ethylaminomethanetriol Chemical compound CCNC(O)(O)O YUPQOCKHBKYZMN-UHFFFAOYSA-N 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
- F16L59/00—Thermal insulation in general
- F16L59/04—Arrangements using dry fillers, e.g. using slag wool
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Mechanical Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3442641 | 1984-11-22 | ||
| DE3442641 | 1984-11-22 | ||
| DE3537656 | 1985-10-23 | ||
| DE19853537656 DE3537656A1 (de) | 1984-11-22 | 1985-10-23 | Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK537685D0 DK537685D0 (da) | 1985-11-21 |
| DK537685A DK537685A (da) | 1986-05-23 |
| DK166541B1 true DK166541B1 (da) | 1993-06-07 |
Family
ID=25826741
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK537685A DK166541B1 (da) | 1984-11-22 | 1985-11-21 | Fremgangsmaade til isolering af isosilybinfrit silibinin |
| DK189491A DK164866C (da) | 1984-11-22 | 1991-11-20 | Fremgangsmaade til isolering af isosilybinfrit silibinin |
| DK199201145A DK172879B1 (da) | 1984-11-22 | 1992-09-17 | Silibininholdigt farmaceutisk præparat |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK189491A DK164866C (da) | 1984-11-22 | 1991-11-20 | Fremgangsmaade til isolering af isosilybinfrit silibinin |
| DK199201145A DK172879B1 (da) | 1984-11-22 | 1992-09-17 | Silibininholdigt farmaceutisk præparat |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4871763A (xx) |
| JP (1) | JPH0678228B2 (xx) |
| AR (1) | AR241268A1 (xx) |
| AT (1) | AT391315B (xx) |
| BE (1) | BE903694A (xx) |
| CA (1) | CA1337125C (xx) |
| CH (1) | CH660008A5 (xx) |
| CS (1) | CS271321B2 (xx) |
| DE (1) | DE3537656A1 (xx) |
| DK (3) | DK166541B1 (xx) |
| EG (1) | EG17710A (xx) |
| ES (2) | ES8609312A1 (xx) |
| FI (1) | FI84065C (xx) |
| FR (1) | FR2573426B1 (xx) |
| GB (1) | GB2167746B (xx) |
| HU (1) | HU195504B (xx) |
| IE (1) | IE59209B1 (xx) |
| IT (1) | IT1207508B (xx) |
| LU (1) | LU86164A1 (xx) |
| MX (1) | MX172175B (xx) |
| NL (1) | NL192204C (xx) |
| NO (1) | NO160206C (xx) |
| PL (1) | PL146889B1 (xx) |
| PT (1) | PT81531B (xx) |
| SE (1) | SE457957B (xx) |
| YU (1) | YU43690B (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3357383B2 (ja) * | 1991-08-14 | 2002-12-16 | 昌宏 黒田 | 低分子化植物性組成物 |
| DE4401902C2 (de) * | 1994-01-24 | 2000-02-03 | Madaus Ag | Verwendung von Flavolignanen als Adjuvans in der Tumortherapie |
| FR2719451B1 (fr) * | 1994-05-04 | 1996-07-26 | Apcis Sa | Utilisation de la silybinine dans le gavage des palmipèdes, en vue de l'obtention d'un foie gras de meilleure qualité. |
| DE19501266A1 (de) * | 1995-01-18 | 1996-07-25 | Madaus Ag | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln |
| US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
| DE69824223T2 (de) | 1997-03-19 | 2004-09-30 | Unilever N.V. | Vorrichtung zum Handhaben von Gegenständen |
| GB2327607B8 (en) * | 1997-07-31 | 2005-03-30 | Litton Internat Company Ltd | A process for producing a herbal extract composition |
| DE10053384A1 (de) * | 2000-10-27 | 2002-05-08 | Bionorica Arzneimittel Gmbh | Pharmazeutische Zubereitung aus Mariendistel und Terpenen |
| US6699900B2 (en) * | 2001-04-07 | 2004-03-02 | Jan E. Zielinski | Hydrophilic and lipophilic silibinin pro-forms |
| DE10360954B3 (de) * | 2003-12-23 | 2005-08-18 | Esparma Gmbh | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen |
| BG65997B1 (bg) * | 2005-03-29 | 2010-09-30 | "Софарма" Ад | Метод за получаване на силибинин |
| WO2009062737A1 (en) * | 2007-11-15 | 2009-05-22 | Madaus Gmbh | Silibinin component for the treatment of hepatitis |
| AU2010247716B2 (en) * | 2009-05-14 | 2015-11-05 | Madaus Gmbh | Amorphous silibinin for the treatment of viral hepatitis |
| WO2011051742A1 (en) * | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
| CN103408539B (zh) * | 2013-08-28 | 2016-04-06 | 天津泰阳制药有限公司 | 高纯度水飞蓟宾的生产方法 |
| WO2017121855A1 (en) * | 2016-01-15 | 2017-07-20 | Universität Hamburg | Flavonoide-type compounds bearing an o-rhamnosyl residue |
| EP4232055A4 (en) | 2020-09-29 | 2024-10-02 | Munisekhar Medasani | EXTRACTION OF BIOACTIVE COMPOUNDS FROM MILK THISTLE PLANT MATERIALS AND USE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773932A (en) * | 1968-06-01 | 1973-11-20 | Madaus & Co Dr | Method for recovering silymarin comprising polyhydroxyphenyl chromanones |
| DE1767666C3 (de) * | 1968-06-01 | 1986-07-31 | Dr. Madaus & Co, 5000 Koeln | Pharmazeutische Zubereitung gegen Lebererkrankungen |
| DE1923082C3 (de) * | 1969-05-06 | 1985-08-22 | Dr. Madaus & Co, 5000 Koeln | Verfahren zur Gewinnung von Polyhydroxyphenylchromanonen (Silymarin I-IV) und Arzneimittel enthaltend das Polyhydroxyphenylchromanon (Silymarin I-IV = Silymarin I-IV-Gruppe)Gemisch |
| DE2416302B2 (de) * | 1974-04-04 | 1978-02-02 | Dr. Madaus & Co, 5000 Köln | Dimeres sowie trimeres silybin und deren n-methylglucaminsalz und verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| BE885558A (fr) * | 1980-10-07 | 1981-04-07 | Madaus & Co Dr | Procede pour l'extraction de silymarine a partir des plantes silymarine ainsi obtenue et son utilisation en therapeutique |
| DE3225688A1 (de) * | 1982-07-09 | 1984-01-12 | Suschnik Matthias Dr | Verfahren zur gewinnung von silymarin aus silybum marianum |
-
1985
- 1985-10-23 DE DE19853537656 patent/DE3537656A1/de active Granted
- 1985-11-11 GB GB08527809A patent/GB2167746B/en not_active Expired
- 1985-11-12 CH CH4854/85A patent/CH660008A5/de not_active IP Right Cessation
- 1985-11-13 LU LU86164A patent/LU86164A1/de unknown
- 1985-11-14 NL NL8503136A patent/NL192204C/nl not_active IP Right Cessation
- 1985-11-18 FI FI854536A patent/FI84065C/fi not_active IP Right Cessation
- 1985-11-19 AT AT0337285A patent/AT391315B/de not_active IP Right Cessation
- 1985-11-20 YU YU1812/85A patent/YU43690B/xx unknown
- 1985-11-20 CS CS858379A patent/CS271321B2/cs unknown
- 1985-11-20 CA CA000495805A patent/CA1337125C/en not_active Expired - Fee Related
- 1985-11-20 SE SE8505488A patent/SE457957B/sv not_active IP Right Cessation
- 1985-11-21 EG EG741/85A patent/EG17710A/xx active
- 1985-11-21 PT PT81531A patent/PT81531B/pt not_active IP Right Cessation
- 1985-11-21 IT IT8522933A patent/IT1207508B/it active
- 1985-11-21 IE IE292785A patent/IE59209B1/en not_active IP Right Cessation
- 1985-11-21 DK DK537685A patent/DK166541B1/da not_active IP Right Cessation
- 1985-11-21 NO NO854657A patent/NO160206C/no unknown
- 1985-11-21 HU HU854449A patent/HU195504B/hu not_active IP Right Cessation
- 1985-11-21 ES ES549119A patent/ES8609312A1/es not_active Expired
- 1985-11-21 PL PL1985256373A patent/PL146889B1/pl unknown
- 1985-11-22 AR AR85302358A patent/AR241268A1/es active
- 1985-11-22 MX MX009231A patent/MX172175B/es unknown
- 1985-11-22 BE BE2/60851A patent/BE903694A/fr not_active IP Right Cessation
- 1985-11-22 FR FR8517320A patent/FR2573426B1/fr not_active Expired
-
1986
- 1986-04-16 ES ES554022A patent/ES8704482A1/es not_active Expired
-
1988
- 1988-03-18 US US07/171,176 patent/US4871763A/en not_active Expired - Fee Related
-
1991
- 1991-01-29 JP JP3009169A patent/JPH0678228B2/ja not_active Expired - Lifetime
- 1991-11-20 DK DK189491A patent/DK164866C/da not_active IP Right Cessation
-
1992
- 1992-09-17 DK DK199201145A patent/DK172879B1/da active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK166541B1 (da) | Fremgangsmaade til isolering af isosilybinfrit silibinin | |
| KR840001776B1 (ko) | 세프타지딤 펜타하이드레이트의 제조방법 | |
| CN104130273B (zh) | 一种头孢曲松钠的合成方法 | |
| FI86854B (fi) | Foerfarande foer framstaellning av kristallina hydrat av cefalosporinsalt. | |
| CN102180890A (zh) | 头孢硫脒水合物及其制备方法和用途 | |
| US4624948A (en) | Crystalline modification of ceftazidim | |
| DK163514B (da) | Fremgangsmaade til fremstilling af en krystallinsk form af natriumsaltet af et oximderivat af 7-aminothiazolylacetamidocephalosporansyre | |
| DK158443B (da) | Fremgangsmaade til stabilisering af et lyophiliseret praeparat indeholdende et alkalimetalsalt af en 7beta-(alfa-carboxy-alfa-arylacetamido)-7alfa-methoxy-3-heterocyklisk thiomethyl-1-dethia-1-oxa-3-cephem-4-carboxylsyre | |
| EP0134568B1 (en) | Stable antibacterial lyophilizates | |
| US4808617A (en) | Lyophilized or precipitated cephalosporin zwitterion and salt combination | |
| CS276849B6 (en) | Process for preparing heat stable crystalline mono chloride | |
| US3928592A (en) | Antibiotic pharmaceutical compositions | |
| JPH01110690A (ja) | 水溶性抗生物質組成物および新規セフェム化合物の水溶性塩類 | |
| FI65069C (fi) | Foerfarande foer framstaellning av kristallvattenfri ny-kristallin form av natrium-7-(d-alfa-formyloxi-alfa-fenylacetamido)-3-(1-metyl-1h-tetrazol-5-yltiometyl)-3-cefem-4-karboxylat | |
| JPS603314B2 (ja) | セフアロスポリン誘導体およびその製造法 | |
| JP2958567B2 (ja) | 非経口用凍結乾燥ｂｍｙ―２８１４２ジ塩酸塩 | |
| EP0169700B1 (en) | Improved pharmaceutical formulations for ceftazidime | |
| JPS636552B2 (xx) | ||
| CA1239390A (en) | Cefonicid monosodium salt | |
| CA1243297A (en) | Crystalline modification of ceftazidim | |
| JP2003514779A5 (xx) | ||
| US4810702A (en) | Antibacterial agent for mammal use comprising cephalosporin derivatives as an effective ingredient | |
| FI83877C (fi) | Foerfarande foer framstaellning av en ny terapeutiskt anvaendbar 7-(3-klorisoxazol-5-yl)-acetamido-3- (1-metyl-1h-1,2,3,4-tetrazol-5-yl)-tiometyl-cef-3-em-4-karboxylsyra | |
| US3258461A (en) | Derivatives of cephalosporin c and related compounds and a method of the synthesis thereof | |
| JPS5936616A (ja) | セフアロスポリン誘導体の安定な医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |